In the First Two Years, Science Alone Isn’t Enough

The pharmaceutical industry has never been more scientifically advanced or more commercially fragile.  Across Cardiovascular, Oncology, Immunology, Neurology, and Rare Disease, there is an unprecedented wave of innovation: 

• Next-generation biologics and cell therapies 
• Precision oncology with biomarker-defined subpopulations 
• Immunology pipelines expanding across multiple indications 
• Neurology breakthroughs in areas long considered intractable 
• Rare disease therapies finally reaching patients at scale 

Yet despite this scientific progress, many launched medicines fail to reach their true potential, not because they lack efficacy, but because their value is not optimally understood, remembered, or applied by physicians. In today’s hyper-competitive, fast-to-market environment, message resonance has become a scientific and commercial imperative. 

The Critical Gap Between Evidence and Uptake 

When a medicine transitions from Clinical Research to Market Access to Brand Marketing, the stakes could not be higher. 

By launch: 

• Hundreds of millions, sometimes billions, have already been invested 
• Payers have set expectations 
• Competitive landscapes are shifting monthly 
• Physicians are overloaded with data, claims, and clinical nuance 

For brands in Years 1–2 of their patent lifecycle, the window to establish: 

• Clear positioning 
• Correct use 
• Clinical confidence 
• Habitual prescribing behavior 

…is remarkably short. 

And yet, most launch strategies still rely on assumptions: 

• Which messages physicians truly understand 
• Which scientific narratives drive confidence 
• Which messages are remembered weeks, not minutes, later 

This is where ROI is silently lost. 

Why Message Resonance Is a Scientific Problem, Not a Creative One 

In complex therapeutic areas like Oncology, Immunology, and Rare Disease, the challenge is not creativity, it’s cognitive load. 

Physicians are being asked to absorb: 

• Novel mechanisms of action 
• New endpoints and surrogate markers 
• Subpopulation data 
• Companion diagnostics 
• Evolving treatment algorithms 

The question is no longer “Is the data strong?”  It is: “Does the data land, stick, and translate into confident action?” 

Our Message Resonance Score™ addresses this challenge by quantifying: 

• HCP understanding 
• Clarity of positioning within the treatment pathway 
• Likelihood of confident use 

This is not market research for insight alone, it is optimization for behavioral impact. If you want to understand how your launch messaging is landing with HCPs in the first two years, get in touch to learn how Message Resonance Score™ can make that visible.